NASDAQ · MREO
Mereo BioPharma Group plc
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MREO: Nov 9, 2026
Mereo BioPharma Group plc American Depositary Shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.01. The reported EPS for the same quarter last year was $-0.01.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Dec 2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Mar 2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Jun 2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · Quiver Quantitative- RTTNews · Aug 15, 2:59 AM EDTWeekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals(RTTNews) – This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts.
- RTTNews · Aug 11, 1:20 PM EDTMereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027(RTTNews) – Mereo BioPharma Group plc (MREO), a clinical-stage biopharmaceutical company focused on rare diseases, recently reported its second-quarter 2026 financial results and provided corporate updates, with investors focusing on its alvelestat partnership, regulatory discuss
- RTTNews · Aug 11, 9:05 AM EDTMereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics(RTTNews) – Sentynl Therapeutics, Inc., a unit of Zydus Lifesciences Limited, on Tuesday said it has entered into an option and license agreement with Mereo BioPharma Group plc (MREO) for U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Defici
- RTTNews · Jan 14, 9:51 AM ESTMereo BioPharma Assessing A Potential Path Forward For Setrusumab In Brittle Bone Disease?(RTTNews) – Mereo BioPharma Group plc (MREO), a clinical-stage biopharmaceutical company, provided an update on its lead programs for its rare-disease product candidates, setrusumab and alvelestat, along with revised cash-runway guidance.
- Zacks · Dec 30, 11:00 AM ESTRARE, MREO Tank as Osteogenesis Study Fails to Meet Primary EndpointUltragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
- Fintel · Dec 22, 7:03 AM ESTNeedham Reiterates Mereo BioPharma Group plc – Depositary Receipt (MREO) Buy RecommendationFintel reports that on December 22, 2025, Needham reiterated coverage of Mereo BioPharma Group plc – Depositary Receipt (NasdaqCM:MREO) with a Buy recommendation. Analyst Price Forecast Suggests 257.00% Upside
- Fintel · Dec 18, 7:03 AM ESTBTIG Reiterates Mereo BioPharma Group plc – Depositary Receipt (MREO) Buy RecommendationFintel reports that on December 18, 2025, BTIG reiterated coverage of Mereo BioPharma Group plc – Depositary Receipt (NasdaqCM:MREO) with a Buy recommendation. Analyst Price Forecast Suggests 271.88% Upside
- Zacks · Jul 10, 10:17 AM EDTRARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year EndUltragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
- Quiver Quantitative · Jul 10, 6:20 AM EDTNew Analyst Forecast: $MREO Given $5.0 Price TargetWe just received data on a new analyst forecast for $MREO. Gil Blum from Needham set a price target of 5.0 for MREO.
- Quiver Quantitative · May 13, 7:43 AM EDTMereo BioPharma Reports Q1 2025 Financial Results and Updates on Phase 3 Orbit Study of Setrusumab for Osteogenesis ImperfectaMereo BioPharma reports progress in its Phase 3 Orbit study for setrusumab and anticipates operational funding through 2027.
- Fintel · Mar 27, 10:58 AM EDTJP Morgan Initiates Coverage of Mereo BioPharma Group plc – Depositary Receipt () (MREO) with Overweight RecommendationFintel reports that on March 27, 2025, JP Morgan initiated coverage of Mereo BioPharma Group plc – Depositary Receipt () (NasdaqCM:MREO) with a Overweight recommendation.
- Quiver Quantitative · Mar 26, 1:15 PM EDTMEREO BIOPHARMA Earnings Results: $MREO Reports Quarterly EarningsMEREO BIOPHARMA ($MREO) posted quarterly earnings results on Wednesday, March 26th. The company reported earnings of -$0.04 per share, missing estimates of -$0.01 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Mereo BioPharma Group plc from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.